Zydus Lifesciences’ NCE Usnoflast receives Fast Track Designation from USFDA

28 May 2025 Evaluate

Zydus Lifesciences’ NCE (novel Chemical Entity) Usnoflast has received ‘Fast Track Designation’ from the United States Food and Drug Administration (USFDA). Usnoflast is a novel oral NLRP3 inhibitor for the treatment of amyotrophic lateral sclerosis (ALS).

A drug that receives Fast Track Designation from the USFDA is eligible for accelerated approval and priority review, if the relevant criteria are met. The purpose of Fast Track Designation is to get important new drugs to the patients faster.

Zydus Lifesciences is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

905.55 -5.95 (-0.65%)
29-Dec-2025 14:38 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.00
Dr. Reddys Lab 1267.35
Cipla 1494.60
Zydus Lifesciences 905.55
Lupin 2086.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×